Drug Pipeline Report

Comprehensive pharmaceutical pipeline intelligence tool that queries 7 data sources in parallel -- clinical trial registries, FDA adverse event reports, FDA drug approvals, FDA drug recalls, PubMed research publications, patent databases, and EMA medicine authorizations -- to produce a composite risk score (0-100) with four specialized scoring models for competitive pipeline threat, first-mover advantage, adverse event divergence, and literature momentum.

Features

• Queries 7 pharmaceutical data sources simultaneously for complete pipeline landscape analysis
• Produces a composite risk score (0-100) graded from CRITICAL to LOW risk level
• Runs four specialized scoring models: Pipeline Threat, First-Mover Advantage, Adverse Event Divergence, and Literature Momentum
• Tracks Phase 3 competitor density as the strongest competitive threat signal
• Analyzes FDA adverse event reports for death reports, serious event ratios, and hospitalization burden
• Measures research publication acceleration to detect emerging therapeutic competition
• Estimates patent exclusivity windows and patent cliff proximity
• Supports filtering by clinical trial phase and pharmaceutical company

Use Cases

• Pharmaceutical Strategists: Assess competitive pressure in a therapeutic area before committing R&D resources. Identify how many Phase 3 competitors are in the pipeline and whether adverse events are creating market openings.
• Biotech Investors: Evaluate drug candidates by quantifying first-mover advantage (patent protection, trial phase lead, existing approvals) against competitive pipeline threat levels.
• Patent Attorneys: Track patent exclusivity windows for drugs in your portfolio and identify approaching patent cliffs that could open the market to generics.
• Pharmacovigilance Teams: Monitor adverse event divergence scores to detect safety signals earlier. The model identifies when death reports, serious event ratios, or hospitalization rates exceed class averages.
• Medical Affairs Teams: Track publication momentum in your therapeutic area to understand research direction and identify potential KOL engagement targets from top publishing journals.

How to Use

1. Click Try for free on this page
2. Enter a Drug Name or Therapeutic Area (e.g., "semaglutide", "GLP-1", "oncology checkpoint inhibitors")
3. Optionally specify a Company Name to focus the analysis (e.g., "Novo Nordisk")
4. Optionally filter by Clinical Trial Phase (Phase 1 through Phase 4)
5. Click Start and wait for the run to finish
6. Download results from the Dataset tab in JSON, CSV, or Excel

Input Parameters

Parameter	Type	Required	Description
query	string	Yes	Drug name, active ingredient, or therapeutic area (e.g., "semaglutide", "GLP-1", "oncology checkpoint inhibitors")
company	string	No	Pharmaceutical company name to focus the analysis (e.g., "Novo Nordisk", "Pfizer")
phase	string	No	Clinical trial phase filter: PHASE1, PHASE2, PHASE3, or PHASE4

Output Example

{
  "company": "Novo Nordisk",
  "drug": "semaglutide",
  "compositeScore": 58,
  "riskLevel": "HIGH",
  "query": "semaglutide",
  "phaseFilter": null,
  "pipelineThreat": {
    "score": 65,
    "competitorCount": 18,
    "phaseDistribution": { "Phase 3": 4, "Phase 2": 6, "Phase 1": 3 },
    "sameIndicationTrials": 13,
    "recentApprovals": 2,
    "threatLevel": "HIGH",
    "signals": ["4 Phase 3 competitors in pipeline", "13 active clinical trials in therapeutic area", "2 recent FDA approvals in class"]
  },
  "firstMoverAdvantage": {
    "score": 72,
    "patentsCovering": 8,
    "earliestPatentExpiry": "2031-06-15",
    "yearsOfExclusivity": 5.3,
    "trialPhaseLead": 4,
    "approvalPathwayClear": true,
    "signals": ["5.3 years patent exclusivity remaining", "Already has 2 FDA approval(s)"]
  },
  "adverseEventDivergence": {
    "score": 35,
    "totalReports": 85,
    "seriousEvents": 18,
    "deathReports": 1,
    "hospitalizationReports": 12,
    "seriousRatio": 0.212,
    "divergenceLevel": "ELEVATED",
    "topReactions": [{ "term": "Nausea", "count": 24 }, { "term": "Vomiting", "count": 15 }]
  },
  "literatureMomentum": {
    "score": 78,
    "publicationCount": 42,
    "recentPublications": 28,
    "accelerating": true,
    "topJournals": ["The New England Journal of Medicine", "The Lancet", "Diabetes Care"],
    "signals": ["28 publications in last 2 years", "Publication rate accelerating (28 recent vs 14 prior 2yr)"]
  },
  "dataSources": {
    "clinicalTrials": 13,
    "fdaAdverseEvents": 85,
    "fdaApprovals": 2,
    "fdaRecalls": 0,
    "pubmedPublications": 42,
    "patents": 8,
    "emaAuthorizations": 3
  }
}

Scoring Model

The composite risk score (0-100) synthesizes four specialized models. Higher score means higher overall risk to your pipeline position.

Pipeline Threat (30% weight, 0-100) -- Quantifies competitive pressure. Phase 3 competitors are the strongest signal at 8 points each (max 40). Active trial density adds up to 20 points. Recent FDA approvals contribute up to 15 points. EMA authorizations add up to 10 points. Competitor recalls reduce the score by up to 15 points (less competition). Threat levels: CRITICAL (75+), HIGH (50-74), MODERATE (25-49), LOW (0-24).

Adverse Event Divergence (25% weight, 0-100) -- Detects safety signal deviation from class norms. Death reports are the strongest divergence indicator at 7 points each (max 35). Serious event ratio above 30% exceeds class average (max 25 points). Hospitalization burden contributes up to 20 points. Report volume adds logarithmic scoring up to 20 points. Divergence levels: CRITICAL (75+), CONCERNING (50-74), ELEVATED (25-49), NORMAL (0-24).

Literature Momentum (25% weight, 0-100) -- Measures research intensity and acceleration. Publication volume scores up to 30 points. Publications in the last 2 years contribute up to 30 points for recency. Publication rate acceleration (20%+ growth threshold) adds up to 25 points. Journal diversity adds up to 15 points. Higher momentum in your therapeutic area means more competitive research activity.

First-Mover Advantage (20% weight, inverted, 0-100) -- Quantifies your defensive position. Patent portfolio strength scores up to 30 points. Years of exclusivity remaining contribute up to 25 points (2.5 points per year). Trial phase lead adds up to 25 points. Existing FDA approvals add up to 20 points. This score is inverted in the composite -- higher first-mover advantage means lower overall risk.

How Much Does It Cost?

Each run costs approximately $0.25-$0.60 in platform credits. The actor calls 7 sub-actors in parallel. On the Apify free tier, you can run approximately 6-10 pipeline analyses per month.

Programmatic Access

Python

from apify_client import ApifyClient
client = ApifyClient("YOUR_API_TOKEN")
run = client.actor("ryanclinton/drug-pipeline-report").call(run_input={
    "query": "semaglutide",
    "company": "Novo Nordisk"
})
for item in client.dataset(run["defaultDatasetId"]).iterate_items():
    print(f"Risk: {item['compositeScore']}/100 — {item['riskLevel']}")
    print(f"Pipeline Threat: {item['pipelineThreat']['threatLevel']}")
    print(f"First-Mover: {item['firstMoverAdvantage']['score']}/100")

JavaScript

import { ApifyClient } from "apify-client";
const client = new ApifyClient({ token: "YOUR_API_TOKEN" });
const run = await client.actor("ryanclinton/drug-pipeline-report").call({
    query: "semaglutide",
    company: "Novo Nordisk"
});
const { items } = await client.dataset(run.defaultDatasetId).listItems();
console.log(items[0].compositeScore, items[0].riskLevel);

FAQ

What does the Adverse Event Divergence score measure? It detects when a drug's safety profile deviates from class norms. It scores death reports, serious event ratios (percentage classified as serious), hospitalization burden, and overall report volume from the FDA Adverse Event Reporting System (FAERS). A CRITICAL divergence level means the safety profile significantly exceeds class averages.

How is patent exclusivity calculated? The actor searches patent databases for relevant patents and estimates years of exclusivity remaining from the earliest patent expiration date. A warning is generated when less than 2 years of exclusivity remain (patent cliff approaching).

Can I compare two competing drugs? Yes. Run the actor once for each drug and compare their composite scores, pipeline threat levels, and first-mover advantage scores. The structured JSON output makes side-by-side comparison straightforward.

What does publication acceleration mean? The Literature Momentum model compares publication output in the last 2 years against the prior 2 years. A 20% or greater increase is classified as "accelerating," indicating growing research interest in the therapeutic area that may signal new competitive entrants.

Does this replace pharmacovigilance systems? No. The Adverse Event Divergence score provides a screening-level view of safety signals. It aggregates publicly available FAERS data and should complement, not replace, established pharmacovigilance processes.

Integrations

Use this actor with:

• Zapier for automated workflows
• Make for complex automations
• Google Sheets for spreadsheet export
• The Apify API for programmatic access